Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics
Leuk Lymphoma
.
2023 Dec;64(12):2037-2041.
doi: 10.1080/10428194.2023.2248329.
Epub 2023 Aug 21.
Authors
Kathleen P L Cheok
1
2
,
Amy A Kirkwood
3
,
Thomas Creasey
4
,
Eleni Tholouli
5
,
Sridhar Chaganti
6
,
Amrith Mathew
6
,
Vaishali Dulobdas
6
,
David Irvine
7
,
Caroline Besley
8
,
Lorna Neil
8
,
Robert Lown
9
,
Tobias Menne
4
,
William Townsend
2
,
Andrea Kuhnl
10
,
Maeve O'Reilly
2
,
Robin Sanderson
10
,
Emilie Sanchez
11
,
Claire Roddie
1
2
Affiliations
1
Research Department of Hematology, University College London, London, UK.
2
Department of Hematology, University College London Hospital, London, UK.
3
Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK.
4
Department of Haematology, Freeman Hospital, Newcastle, UK.
5
Department of Haematology, Manchester Royal Infirmary, Manchester, UK.
6
Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK.
7
Department of Haematology, Queen Elizabeth University Hospital, Glasgow, UK.
8
Department of Haematology, University Hospitals Bristol and Weston NHS Foundation Trusts, Bristol, UK.
9
Department of Haematology, Southampton General Hospital, Southampton, UK.
10
Department of Haematology, King's College Hospital, London, UK.
11
Department of Virology, University College London Hospital, UK.
PMID:
37602678
DOI:
10.1080/10428194.2023.2248329
No abstract available
MeSH terms
COVID-19* / prevention & control
Humans
Immunotherapy, Adoptive
Receptors, Chimeric Antigen*
Vaccination
Substances
Receptors, Chimeric Antigen